IDMS肌酐时代Cockcroft-Gault公式估算GFR用于卡铂剂量不再足够准确
该多中心回顾性研究纳入550例同时有51Cr-GFR和CG-GFR的患者,发现CG-GFR与51Cr-GFR比值波动大,按AUC6给药可致18%剂量不足、23%过量超过100mg。基于51Cr-GFR的AUC5与基于CG-GFR的AUC6等效的惯例不成立,应废除;无51Cr-GFR时建议将CG-GFR上限设为125 mL/min。
要点
- CG-GFR与51Cr-GFR比值仅1.04,但13%患者<0.8、33%>1.2
- 按AUC6给药,18%剂量不足、23%过量超过100mg
- BMI>35、女性、恶性肿瘤为CG-GFR高估危险因素
核心结论
- 基于51Cr-GFR的AUC5与基于CG-GFR的AUC6等效的惯例无效,应废弃。
- 无51Cr-GFR时,推荐将CG-GFR上限设为125 mL/min。
研究设计与样本
- 多中心回顾性研究,纳入550例有51Cr-GFR及匹配CG-GFR的患者。
- 中位年龄62岁(范围19-90),64%为女性。
- GFR评估指征:恶性肿瘤85%、活体肾捐献评估12%、其他3%。
主要发现
- CG-GFR与51Cr-GFR中位比值1.04(范围0.43-3.38)。
- 比值<0.8者72例(13%),>1.2者180例(33%)。
- 按AUC6给药,18%患者剂量不足、23%过量超过100mg(与51Cr-GFR比)。
- CG-GFR高估危险因素:BMI>35(MPE 39%)、女性(MPE 15%)、恶性肿瘤(MPE 11%)。
- BMI<20为低估危险因素(MPE -3.5%)。
关键数值与推荐
- 以基于51Cr-GFR的AUC5卡铂剂量为参考标准。
- CG-GFR上限125 mL/min时,按AUC6给药仍有18%剂量不足、23%过量超过100mg。
临床怎么用
- 不应将基于CG-GFR的AUC6等同于基于51Cr-GFR的AUC5。
- 无51Cr-GFR时,建议将CG-GFR上限设为125 mL/min。
- 对BMI>35、女性、恶性肿瘤患者需警惕CG-GFR高估。
局限性
- 回顾性研究设计。
- 未报告51Cr-GFR不可及时的具体替代方案验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Glomerular filtration rate (GFR) measured by Chromium-51-EDTA excretion (51Cr-GFR) is considered the gold standard of renal function assessment, but serum creatinine in the Cockcroft-Gault (CG) formula is routinely used to estimate GFR for carboplatin dosing. Serum creatinine measured by isotope-dilution-mass-spectrometry (IDMS) can generate spuriously high GFR estimates when used in the CG formula. We hypothesized that GFR calculated using IDMS-creatinine in the CG formula (CG-GFR) exposes patients to inaccurate carboplatin dosing. METHODS: This is a multicenter retrospective study of patients who had a 51Cr-GFR assessment for malignant or non-malignant indications, with a matched CG-GFR. Carboplatin dose based on 51Cr-GFR at AUC5 was used as the reference. RESULTS: 550 patients were analyzed, median age 62 (19-90), 64% female. Indication for GFR evaluation: malignancy (85%), assessment for live kidney donation (12%), other (3%). Median ratio of CG-GFR: 51Cr-GFR 1.04 (0.43-3.38); <0.8 in 72 patients (13%), >1.2 in 180 patients (33%). Despite capping of CG-GFR at 125 mL/min, dosing according to AUC6 would have resulted in 18% of patients being underdosed and 23% overdosed by >100 mg compared to 51Cr-GFR. Subgroup analysis identified BMI (>35, MPE 39%), gender (female MPE 15%), GFR indication (malignancy MPE 11%) as risk factors for overestimate of CG-GFR, and BMI < 20 for underestimate (MPE -3.5%). CONCLUSIONS: The convention of considering AUC5 carboplatin based on 51Cr-GFR, and AUC6 carboplatin based on CG-GFR as equivalent is invalid and should be abandoned. When 51Cr-GFR is unavailable, capping CG-GFR at 125 mL/min is recommended.
引用
- McLean L, Whittle JR, Graham J, et al. Carboplatin dosing in the era of IDMS-creatinine; the Cockroft-Gault formula no longer provides a sufficiently accurate estimate of glomerular filtration rate for routine use in clinical care. Gynecol Oncol. 2020. PMID: 32220419. doi:10.1016/j.ygyno.2020.03.017
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。